nathalie goemans

associate professor- Emeritus

Katholieke Universiteit Leuven

Belgium

Research Interests

Explore related searches

Professors in Belgium Professors in Medical Science Medical Science professors in Belgium

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Dr. Nathalie Goemans is an Associate Professor Emeritus at Katholieke Universiteit Leuven, Belgium. Her research primarily focuses on Duchenne muscular dystrophy and spinal muscular atrophy, exploring areas such as muscle impairments, neurobehavioral difficulties, and the efficacy of innovative treatments. She has published extensively on the longitudinal impact of these conditions and the methodologies for evaluating treatment outcomes.

Articles (8)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2020

Collaborators (4)

Giovanni Baranello

Prof.

University College London

UNITED KINGDOM

View details

Francesco Muntoni

University College London

UNITED KINGDOM

View details

Erik H. Niks

Leiden University Medical Center

NETHERLANDS

View details

Kayoko Saito

Director & Professor

Tokyo Women's Medical University

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

nathalie goemans

Research Interests

Explore related searches

Contact this professor

About

Articles (8)

Longitudinal interaction between muscle impairments and gait pathology in growing children with Duchenne muscular dystrophy

Development and Pilot Validation of the DuMAND Checklist to Screen for Duchenne Muscular Dystrophy-Associated Neurobehavioral Difficulties (DuMAND)

Duchenne Muscular Dystrophy-Associated Neurobehavioral Difficulties: Insights from Clinical Practice

DMD Genotypes and Motor Function in Duchenne Muscular Dystrophy

Correction to: Two‑year efficacy and safety of risdiplam in patients with type 2 or non‑ambulant type 3 spinal muscular atrophy (SMA)

Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)

Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls

Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration

Collaborators (4)

Giovanni Baranello

Francesco Muntoni

Erik H. Niks

Kayoko Saito

Make your next move.